Aura Biosciences prices Nasdaq IPO (1244635)
October 29 2021 - 01:00AM
UK Regulatory
Arix Bioscience PLC (ARIX) Aura Biosciences prices Nasdaq IPO
29-Oct-2021 / 07:00 GMT/BST Dissemination of a Regulatory
Announcement, transmitted by EQS Group. The issuer is solely
responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Update
Aura Biosciences prices Nasdaq IPO
LONDON, 29 October 2021: Arix Bioscience plc (LSE: ARIX,
"Arix"), a global venture capital company focused on investing in
and building breakthrough biotech companies, today notes that its
portfolio company, Aura Biosciences, Inc., ("Aura"), has announced
the pricing of its initial public offering of 5,400,000 shares of
common stock at a public offering price of USD14.00 per share for
aggregate gross proceeds of USD75.6 million. In addition, Aura has
granted the underwriters an option for a period of 30 days to
purchase up to 810,000 additional shares of common stock. All of
the shares are being offered by Aura. Aura's common stock is
expected to begin trading on the Nasdaq Global Market on 29 October
2021 under the ticker symbol "AURA".
The IPO resulted in a GBP3.7 million[1] (2.8p per share)
increase in the value of Arix's existing holding in Aura, which was
valued at GBP11.7 million at 30 June 2021[2].
A registration statement relating to these securities has been
filed with and declared effective by the U.S. Securities and
Exchange Commission. This announcement does not constitute an offer
to sell or the solicitation of an offer to buy securities, and
shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities Act
of 1933, as amended.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Manel Mateus
+44 (0)20 8078 4357
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences. We collaborate with
exceptional entrepreneurs and provide the capital, expertise and
global networks to help accelerate their ideas into important new
treatments for patients. As a listed company, we are able to bring
this exciting growth phase of our industry to a broader range of
investors.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage oncology company
developing a novel technology platform based on virus-like drug
conjugates (VDCs) to target and destroy cancer cells selectively
while activating the immune system to create long lasting
anti-tumor immunity. The VDC technology platform is based on the
discoveries of NIH Distinguished Investigator Dr. John Schiller of
the Center for Cancer Research at the National Cancer Institute
(NCI). The company has the goal of developing this technology in
multiple cancer indications with an initial focus on primary
choroidal melanoma, a rare disease for which there are no approved
drugs. Aura's lead product candidate belzupacap sarotalocan
(AU-011) is currently in Phase 2 development for the first line
treatment of primary choroidal melanoma, a vision and
life-threatening form of eye cancer where standard of care
radioactive treatments leave patients with major vision loss and
severe comorbidities. AU-011 was well tolerated in a Phase 1b/2
trial, demonstrating high rates of tumor control and vision
preservation. Future pipeline applications for Aura's technology
include additional ocular oncology indications like choroidal
metastases and solid tumor indications like non-muscle invasive
bladder cancer. Aura is headquartered in Cambridge, MA. For more
information, visit www.aurabiosciences.com.
[] At exchange rate on 28 October 2021
[2] At exchange rate on 30 June 2021
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 125512
EQS News ID: 1244635
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1244635&application_name=news
(END) Dow Jones Newswires
October 29, 2021 02:00 ET (06:00 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Mar 2023 to Mar 2024